Portal de investigación
An Open-Label, Prospective, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of TheraSphere™ Followed by Durvalumab (Imfinzi®) with Tremelimumab (Imjudo®) for Hepatocellular Carcinoma (HCC).
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
BIOCOMPATIBLES UK LTD
Cita
An Open-Label, Prospective, Multi-Center Clinical Trial to Evaluate the Efficacy and Safety of TheraSphere™ Followed by Durvalumab (Imfinzi®) with Tremelimumab (Imjudo®) for Hepatocellular Carcinoma (HCC). (S2472). BIOCOMPATIBLES UK LTD. 2024IP:ROBERTO PEDRO DÍAZ BEVERIDGE.